Antileukotriene therapy: Future directions

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 2 II, 2000, Pages

  Holgate, Stephen T ^a   Sampson, Anthony P ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; ZAFIRLUKAST;

ASTHMA; BRONCHUS HYPERREACTIVITY; DRUG EFFICACY; EOSINOPHIL; FORCED EXPIRATORY VOLUME; GENETIC VARIABILITY; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW;

EID: 0034095372     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.supplement_1.ltta-29     Document Type: Review

References (75)

1. Brocklehurst, W. E. 1953. Occurrence of an unidentified substance during anaphylactic shock in cavy lung. J. Physiol. 120:16-17.
2. Holgate, S. T., P. Bradding, and A. P. Sampson. 1996. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J. Allergy Clin. Immunol. 98:1-13.
3. 4 receptor antagonist, in subjects with bronchial asthma. Am. J. Respir. Crit. Care Med. 150:618-623.
4. Kuitert, L., and N. C. Barnes. 1995. PAF and asthma - time for an appraisal? Clin. Exp. Allergy 25:1159-1162.
5. Hay, D. W. P., T. J. Torphy, and B. J. Undem. 1995. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol. Sci. 16:304-309.
6. Shi, H. Z., C. Q. Xiao, D. Zhong, S. M. Qin, Y. Liu, G. R. Liang, H. Xu, Y. Q. Chen, X. M. Long, and Z. F. Xie. 1998. Effect of inhaled interleukin-5 on airway hyperreactivity and cosinophilia in asthmatics. Am. J. Respir. Crit. Care Med. 157:204-209.
7. Holroyde, M. C., R. E. C. Altounyan, M. Cole, M. Dixon, and E. V. Elliott. 1981. Bronchoconstriction produced in man by leukotrienes C and D. Lancet ii:17-18.
8. 4-receptor antagonist. Eur. J. Pharmacol. 191: 273-280.
9. 4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am. J. Respir. Crit. Care Med. 154:850-857.
10. 4 and granulocytic infiltration into asthmatic airways. Lancet 341:989-990.
11. 4 and methacholine on sputum cell differentials in asthma. Am. J. Respir. Crit. Care Med. 155:1247-1253.
12. Kane, G. C., M. Tollino, M. Pollice, C. J. Kim, J. Cohn, J. J. Murray, R. Dworski, J. Sheller, J. E. Fish, and S. P. Peters. 1995. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor. Prostaglandins 50:1-18.
13. Foster, A., and C. C. Chan. 1991. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively-sensitised guinea pig. Int. Arch. Allergy Appl. Immunol. 96:279-284.
14. 4 receptor antagonism reduces airway hyperresponsiveness in monkeys. Pulm. Pharmacol. 7:49-58.
15. Abraham, W. M., A. Ahmed, A. Cortes, M. W. Sielczak, W. Hinz, J. Bouska, C. Lanni, and R. L. Bell. 1992. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep, Enr. J. Pharmacol. 217:119-126.
16. Irvin, C. G., Y.P. Tu, J. R. Sheller, and C. D. Funk. 1997. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am. J. Physiol. 272:L1053-L1058.
17. Calhoun, W. J., B. J. Lavins, M. C. Minkwitz, R. Evans, G. J. Gleich, and J. Cohn. 1998. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am. J. Respir. Crit. Care Med. 157:1381-1389.
18. Kane, G. C., M. Pollice, C. Kim, J. Cohn, R. T. Dworski, J. J. Murray, J. R. Sheller, J. E. Fish, and S. P. Peters. 1996. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J. Allergy Clin. Immunol. 97:646-654.
19. Wenzel, S. E., J. B. Trudeau, D. A. Kaminsky, J. Cohn, R. J. Martin, and J. Y. Westcott. 1995. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am. J. Respir. Crit. Care Med. 152:897-905.
20. Leff, J. A., E. Pizzichini, A. Efthimiadis, L. P. Boulet, L. X. Wei, D. E. Weinland, L. Hendeles, and F. E. Hargreave. 1997. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomised placebo-controlled trial (abstract). Am. J. Respir. Crit. Care Med. 155:A977.
21. Isogai, S., M. Taniguchi, K. Anzai, C. Nakagawa, K. Matsui, I. Tanaka, K. Kako, M. Sato, M. Okazawa, H. Sakakibara, and S. Suetsugu. 1998. Effects of peptide-leukotriene receptor antagonist pranlukast on eosinophil counts in peripheral blood and sputum in patients with chronic asthma (abstract). Am. J. Respir. Crit. Care Med. 157:A412.
22. Knorr, B., J. Matz, J. A. Bernstein, H. Nguyen, B. C. Seidenberg, T. F. Reiss, and A. Becker. 1998. Montelukast for chronic asthma in 6-to 14-year-old children: a randomized, double-blind trial. J.A.M.A. 279: 1181-1186.
23. Reiss, T. F., P. Chervinsky, R. J. Dockhorn, S. Shingo, B. Seidenberg, and M. D. Edwards. 1998. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multi-center, randomized, double-blind trial. Arch. Intern. Med. 158:1213-1220.
24. Kylstra, J. W., D. E. Sweitzer, C. J. Miller, and C. M. Bonucelli. 1998. Zafirlukast (Accolate) in moderate asthma: patient-reported outcomes and peripheral eosinophil data from a 13-week trial (abstract). Am. J. Respir. Crit. Care Med. 157:A410.
25. 4 synthase in bronchial biopsies of aspirin-intolerant asthmatics. J. Clin. Invest. 101: 834-846.
26. Seymour, M. L., D. Aberg, G. Riise, S. Rak, S. T. Holgate, and A. P. Sampson. 1998. Seasonal allergen exposure increases expression of leukotriene pathway enzymes and induces eosinophil influx in bronchial mucosa of atopic asthmatics (abstract). J. Allergy Clin, Immunol. 101:711.
27. 4 effects on human eosinophil and neutrophil motility in vitro. J. Leukocyte Biol. 55:183-191.
28. Sehmi, R., A. J. Wardlaw, O. Cromwell, K. Kurihara, P. Waltmann, and A. B. Kay. 1992. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 79:2952-2959.
29. 4, histamine, and bradykinin on cytosolic calcium concentrations and adhesiveness of endothelial cells and neutrophils. Clin. Exp. Immunol. 103:454-460.
30. 4 induces P-selectin and sialyl-Lewis-X-dependent alterations in leukocyte kinetics in vivo. Circ. Res. 77:879-887.
31. 1 receptor-mediated mechanism. J. Pharmacol. Exp. Ther. 281:655-662.
32. Wein, M., S. A. Sterbinsky, C. A. Bickel, R. P. Schleimer, and B. S. Bochner. 1995. Comparison of human eosinophil and neutrophil ligands for P-selectin: ligands for P-selectin differ from those for E-selectin. Am. J. Respir. Cell Mol. Biol. 12:315-319.
33. Sano, H., N. Nakagawa, H. Nakajima, S. Yoshida, and I. Iwamoto. 1995. Role of vascular cell adhesion molecule-1 and platelet-activating factor in selective eosinophil migration across vascular endothelial cells. Int. Arch. Allergy Immunol. 107:533-540.
34. Nagata, M., J. B. Sedgwick, H. Kita, and W. W. Busse. 1998. Granulocyte macrophage colony-stimulating factor augments ICAM-1 and VCAM-1 activation of eosinophil function. Am. J. Respir. Cell Mol. Biol. 19:158-166.
35. Ortiz, J. L., I. Gorenne, J. Cortijo, A. Seller, C. Labat, B. Sarria, T. S. Ahram, P. J. Gardiner, E. Morcillo, and C. Brink. 1995. Leukotriene receptors on human pulmonary vascular endothelium. Br. J. Pharmacol. 115:1382-1386.
36. Gardiner, P. J., T. S. Abram, S. R. Tudhope, N. J. Cuthbert, P. Norman, and C. Brink. 1994. Leukotriene receptors and their selective antagonists. Adv. Prostaglandin Thromboxane Leukotriene Res. 22:49-61.
37. Hebert, M. J., T. Takano, H. Holthofer, and H. R. Brady. 1996. Sequential morphologic events during apoptosis of human neutrophils: modulation by lipoxygenase-derived eicosanoids. J. Immunol. 157:3105-3115.
38. Koller, M., P. Wachtler, A. David, G. Muhr, and W. Konig. 1997. Arachidonic acid induces DNA-fragmentation in human polymorpho-nuclear neutrophil granulocytes. Inflammation 21:463-474.
39. 4 receptor blockade (abstract). Am. J. Respir. Crit. Care Med. 157:A142.
40. Dittmann, K. H., C. Mayer, H. P. Rodemann, P. E. Petrides, and C. Denzlinger. 1998. MK-886, a leukotriene biosynthesis inhibitor, induces antiproliferative effects and apoptosis in HL-60 cells. Leukocyte Res. 22:49-53.
41. Melis, M., L. Siena, E. Pace, A. M. Vignola, G. Garinoff, F. Cibella, M. Gjomarkaj, and G. Bonsignore. 1998. Effect of zafirlukast on peripheral blood T-lymphocytes (PBT) isolated from normal and asthmatic patients (abstract). Am. J. Respir. Crit. Care Med. 157:A394.
42. 4 in response to soluble agonists. J. Immunol. 147:3855-3861.
43. 4 transcriptionally activates interleukin-6 expression involving NK-κB and NF-1L6. Eur. J. Immunol. 22: 2705-2711.
44. 4 induces interleukin 5 generation from human T lymphocytes. Eur. J. Immunol. 23:2392-2398.
45. 4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J. Allergy Clin, Immunol. 96:643-651.
46. Kohno, S., N. Tsuzuike, H. Yamamura, T. Nabe, M. Horiba, and K. Ohata. 1993. Important role of peptide leukotrienes (p-LTs) in the resting tonus of isolated human bronchi. Jpn. J. Pharmacol. 62:351-355.
47. Malaviya, R., and B. A. Jakschik. 1993. Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. J. Biol. Chem. 268:4939-4944.
48. 4 production in asthma of different severities. Eur. Respir. J. 8:1465-1472.
49. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J. Allergy Clin. Immunol. 82:654-660.
50. Taki, F., R. Suzuki, K. Torii, S. Matsumoto, H. Taniguchi, and K. Takagi. 1994. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate. Arzneimittelforschung. 44:330-333.
51. Rosenthal, R. R., B. J. Lavins, and L. A. Hanby. 1996. Effect of treatment with zafirlukast (Accolate) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma (abstract). J. Allergy Clin. Immunol. 97:250.
52. Fischer, A. R., C. A. McFadden, R. Frantz, W. M. Awni, J. Cohn, J. M. Drazen, and E. Israel. 1995. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am. J. Respir. Crit. Care Med. 152:1203-1207.
53. 4 in allergen-induced increases in airway smooth muscle in the rat. Am. Rev. Respir. Dis. 148:413-417.
54. 4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am. J. Respir. Cell Mol. Biol 19:453-461.
55. Amishima, M., M. Munakata, Y. Nasuhara, A. Sato, T. Takahashi, Y. Homma, and Y. Kawakami. 1998. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am. J. Respir. Crit. Care Med. 157:1907-1912.
56. Belvisi, M. G., M. Saunders, M. Yacoub, and J. A. Mitchell. 1998. Expression of cyclooxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth. Br. J. Pharmacol. 125: 1102-1108.
57. 4 upregulates collagenase expression and synthesis in human lung fibroblasts. Biochim. Biophys. Acta 1224:168-174.
58. Leikauf, G. D., H. E. Claesson, C. A. Doupnik, S. Hybbinette, and R. C. Grafstrom. 1990. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am. J. Physiol. 259:L255-L261.
59. McAlexander, M. A., A. C. Myers, and B. J. Undem. 1998. Inhibition of 5-lipoxygenase diminishes neurally evoked tachykinergic contraction of guinea pig isolated airway. J. Pharmacol. Exp. Ther. 285:602-607.
60. Funk, C. D., S. Hoshiko, T. Matsumoto, O. Rådmark, and B. Samuelsson. 1989. Characterization of the human 5-lipoxygenase gene. Proc. Natl. Acad. Sci. U.S.A. 86:2587-2591.
61. Hoshiko, S., O. Rådmark, and B. Samuelsson. 1990. Characterization of the human 5-lipoxygenase promoter. Proc. Natl. Acad. Sci. U.S.A. 87: 9073-9077.
62. Kennedy, B. P., R. E. Diehl, Y. Boie, M. Adam, and R. A. Dixon. 1991. Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). J. Biol. Chem. 266:8511-8516.
63. In, K., K. Asano, D. Beler, J. Grobholz, P. W. Finn, E. K. Solverman, E. S. Silverman, T. Collins, A. R. Fischer, T. P. Keith, K. Serino, S. W. Kim, G. W. De Sanctis, C. Yandava, A. Pillari, P. Rubin, J. Kemp, E. Israel, W. Busse, and J. M. Drazen. 1997. Naturally-ocurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest. 99:1130-1137.
64. Drazen, J. M. 22nd Symposium of Collegium Internationale Allergologicum, Corfu, September 1998, Abstract 39.
65. Szczeklik, A., K. Sladek, R. Dworski, E. Nizankowska, J. Soja, J. Sheller, and J. Oates. 1996. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 154:1608-1614.
66. 4, and histamine in asthmatics. Am. Rev. Respir. Dis. 146:96-103.
67. 4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int. Arch. Allergy Immunol. 113:355-357.
68. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350:1599-1600.
69. 2 does not alter leukotriene formation. J. Biol. Chem. 272:759-765.
70. Shamsuddin, M., E. Chen, J. Anderson, and L. J. Smith. 1997. Regulation of leukotriene and platelet-activating factor synthesis in human alveolar macrophages. J. Lab. Clin. Med. 130:615-626.
71. 2. Blood 91:3037-3043.
72. 4. Proc. Natl. Acad. Sci. U.S.A. 89:11598-11602.
73. 4 and structurally related conjugates. J. Biol. Chem. 269:27807-27810.
74. Capra, V., S. Nicosia, D. Ragnini, M. Mezzetti, D. Keppler, and G. E. Rovati. 1998. Identification and characterization of two cysteinyl-leukotriene high affinity binding sites with receptor characteristics in human lung parenchyma. Mol. Pharmacol. 53:750-758.
75. Woods, J. W., M. J. Coffey, T. G. Brock, I. I. Singer, and M. Peters-Golden. 1995. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Invest. 95:2035-2046.